WHO technical advisory group to discuss Covaxin EUL on October 26
Hyderabad: The technical advisory group of the World Health Organisation (WHO) will meet on October 26 to consider emergency use listing for Bharat Biotech's COVID-19 vaccine Covaxin, tweeted Soumya Swaminathan, chief scientist of the global health body, on Sunday.
"The technical advisory group will meet on Oct 26th to consider EUL for #Covaxin. @WHO has been working closely with @BharatBiotech to complete the dossier. Our goal is to have a broad portfolio of vaccines approved for emergency use & to expand access to populations everywhere," she tweeted.
The Strategic Advisory Group of Experts on Immunization (SAGE) of the WHO which held a meeting on October 6 to make its recommendations on Covaxin on EUL, among other issues, had earlier said it will take a call on granting EUL status to Covaxin in a week time.
The EUL process being carried out by the WHO and the Technical Advisory Group of independent experts - is centered on determining if a manufactured product such as vaccine is quality-assured, safe and effective, WHO earlier said.
"The WHO is currently reviewing the data submitted by the vaccine maker and the date for a decision on the jab is "October 2021" according to the update available on the WHO website," reports PTI.
The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) high containment facility.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.